Rehmann Capital Advisory Group’s Neurocrine Biosciences NBIX Stock Holding History

Rehmann Capital Advisory Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.43M	Buy	+8,460	New	+$1.26M	0.07%	208
2019 Q3	–	Sell	-534	Closed	-$45.1K	–	1975
2019 Q2	$45.1K	Sell	534 -4	-0.7%	-$328	0.01%	872
2019 Q1	$47.4K	Sell	538 -10	-2%	-$836	0.01%	827
2018 Q4	$39.1K	Sell	548 -9	-2%	-$862	0.01%	666
2018 Q3	$68.5K	Buy	557 +197	+55%	+$22.4K	0.01%	695
2018 Q2	$35.4K	Buy	360 +14	+4%	+$1.25K	0.01%	903
2018 Q1	$29K	Buy	+346	New	+$29.2K	﹤0.01%	956

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Rehmann Capital Advisory Group's NBIX Position: Q2 2026 in Review

Rehmann Capital Advisory Group opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 8,460 shares worth $1.43M. The stake represents 0.07% of the portfolio and ranks #208 among its holdings. This is a return to the name: Rehmann Capital Advisory Group previously reported a position in NBIX as recently as Q2 2019.

Rehmann Capital Advisory Group first reported a position in NBIX in Q1 2018 and has held it in 7 quarters since. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Rehmann Capital Advisory Group held 8,460 shares of Neurocrine Biosciences worth $1.43M as of Q2 2026.
Neurocrine Biosciences was a new Rehmann Capital Advisory Group position in Q2 2026.
Neurocrine Biosciences made up 0.07% of Rehmann Capital Advisory Group's portfolio in Q2 2026, its #208 holding.
Rehmann Capital Advisory Group first reported a position in Neurocrine Biosciences in Q1 2018 and has held it in 7 quarters since.
779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Rehmann Capital Advisory Group's 13F filing for Q2 2026, filed 20 Aug 2026.